interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Bempedoic Acid; Ezetimibe

Generic competition · all medicines · read 12 November 2026

Is there a generic of Bempedoic Acid; Ezetimibe, and who makes it?

Bempedoic Acid; Ezetimibe appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Bempedoic Acid; Ezetimibe1 dosage-form group in the Orange Book
0generic makers listed
  1. Bempedoic Acid; Ezetimibe appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Nexlizet. No generic is listed as marketed.

2020202520302035204001brand 2020data datePatent 7335799 listed to expire 3 December 2030Patent 11744816 listed to expire 14 March 2036Patent 10912751 listed to expire 14 March 2036Patent 11926584 listed to expire 19 June 2040Patent 12404227 listed to expire 19 June 2040Patent 11613511 listed to expire 19 June 2040Patent 11760714 listed to expire 19 June 2040Patent 12398087 listed to expire 19 June 2040Exclusivity I-943 to 22 March 2027Exclusivity I-945 to 22 March 2027
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 22 March 2027Exclusivity I-943 Nexlizet
  • 22 March 2027Exclusivity I-945 Nexlizet
  • 3 December 2030Patent 7335799 drug substance
  • 14 March 2036Patent 11744816
  • 14 March 2036Patent 10912751
  • 19 June 2040Patent 11926584
  • 19 June 2040Patent 12404227 drug substance
  • 19 June 2040Patent 11613511 drug substance
  • 19 June 2040Patent 11760714 drug product
  • 19 June 2040Patent 12398087 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.